Evaluation of Clinical Approach and Outcomes Staphylococcus aureus Bacteremia

dc.contributor.authorYanik Yalcin, Tugba
dc.contributor.authorErol, Cigdem
dc.contributor.authorDemirkaya, Melike Hamiyet
dc.contributor.authorDurukan, Elif
dc.contributor.authorKurt Azap, Ozlem
dc.contributor.orcID0000-0002-3171-8926en_US
dc.contributor.orcID0000-0001-5996-8639en_US
dc.contributor.orcID0000-0002-8579-5564en_US
dc.contributor.orcID0000-0002-2535-2534en_US
dc.contributor.pubmedID38633900en_US
dc.contributor.researcherIDAAK-4089-2021en_US
dc.contributor.researcherIDAAA-4708-2022en_US
dc.contributor.researcherIDAAJ-8621-2021en_US
dc.contributor.researcherIDAAJ-1219-2021en_US
dc.date.accessioned2024-07-30T11:29:28Z
dc.date.available2024-07-30T11:29:28Z
dc.date.issued2023
dc.description.abstractObjective: Despite appropriate treatment and early diagnosis methods, Staphylococcus aureus bacteremia (SAB) is still associated with a high mortality rate. This study aims to evaluate the clinical features and approaches to SAB and to analyze the parameters that may affect 7-day and 30-day mortality. Materials and Methods: Adult patients with SAB data between 2011 and 2018 were evaluated retrospectively. Clinical data, patient demographics, and 7-day and 30-day mortality rates were obtained from their medical records.Results: In total, 144 patients were included in the study; 57.6% (83/144) of patients were men, and the mean age was 65.2 +/- 16.5 years. The most common source of infection was the central-line catheter (38.9%), followed by intra-abdominal (21%), respiratory (16.7), infective endocarditis (5.6%), and osteoarticular foci (2.1%). Fifteen percent (15%) of the strains were methicillin resistant. Transthoracic echocardiography (TTE) was performed for 80.6% (116/144) patients. Infectious diseases specialist consultation within 96 hours from blood culture signal was requested in 79.9%. Overall, 7-day mortality was 11.8%, and 30-day mortality was 21.5%. Staying in intensive care units (ICU) increased the risk of 30-day mortality by 1.1 times, and respiratory-focused SAB increased the risk by 4.3 times.Conclusion: SAB is still a big threat. Staphylococcal pneumonia remains a severe infection. Several prognostic factors influence mortality. Identifying the source, ensuring source control, and appropriate initial therapy as soon as possible are critical for reducing mortality and morbidity in SAB.en_US
dc.identifier.endpage39en_US
dc.identifier.issn2667-646Xen_US
dc.identifier.issue1en_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986690/pdf/IDCM-5-1-191.pdf
dc.identifier.urihttp://hdl.handle.net/11727/12172
dc.identifier.volume5en_US
dc.identifier.wos001085178000005en_US
dc.language.isoengen_US
dc.relation.isversionof10.36519/idcm.2023.191en_US
dc.relation.journalINFECTIOUS DISEASES AND CLINICAL MICROBIOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectStaphylococcus aureusen_US
dc.subjectbacteremiaen_US
dc.subjectstaphylococcal pneumoniaen_US
dc.subjectmortalityen_US
dc.titleEvaluation of Clinical Approach and Outcomes Staphylococcus aureus Bacteremiaen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
IDCM-5-1-191.pdf
Size:
176.56 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: